NCI172112 is a classical bifunctional alkylating agent synthesized in an effort to develop antitumor agents effective against CNS tumors.

NCI172112 (Spirohydantoin mustard, SHM) might serve as a carrier to cross the blood brain barrier. The cumulative excretion of radioactivity in the urine and faeces of rats after administration of [2-chloroethyl-U-¹⁴C]NCI172112 or [hydantoin-4-¹⁴C]NCI172112 ( 3.13 mg/kg. i.v.) is measured. Four hours after dosing, a significantly (P<0.005) greater amount of radioactivity has been excreted in the urine of rats treated with [hydantoin-¹⁴C]NCI172112 than with [ethyl-¹⁴C]NCI172112. However, by 24 h, approx.50% of dose is recovered in the urine with both labelled materials. Clearance of radioactivity in the faeces is slow, but, as for the renal excretion, is significantly greater for the hydantoin-¹⁴C moiety. No radioactivity is found in the expired air of a rat receiving a single dosing of [hydantoin-¹⁴C]NCI172112 and less than 1% is measured after administration of [ethyl-¹⁴C]NCI172112. Renal clearance of radioactivity is similar 4 h after administration of [¹⁴C]NCI172112 to rats with biliary cannulas, with 14.1±2.9 and 17.5±2.1% of the ethyl-¹⁴C and 34.5±2.5 and 33.1±6.3%, of the hydantoin-¹⁴C dose appearing in the urine after dosing with 3.13 and 6.25 mg/kg, respectively. A difference in the 4 h urinary excretion of the two labels also is observed in dogs given [¹⁴C]NCI172112 (1 mg/kg, i.v.). The percentages of hydantoin-¹⁴C and ethyl-¹⁴C eliminated are 29.4±2.7% and 17.2±3.5%, respectively (P<0.05).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

NCI172112 (Spirohydantoin mustard, SHM) might serve as a carrier to cross the blood brain barrier. The cumulative excretion of radioactivity in the urine and faeces of rats after administration of [2-chloroethyl-U-¹⁴C]NCI172112 or [hydantoin-4-¹⁴C]NCI172112 ( 3.13 mg/kg. i.v.) is measured. Four hours after dosing, a significantly (P<0.005) greater amount of radioactivity has been excreted in the urine of rats treated with [hydantoin-¹⁴C]NCI172112 than with [ethyl-¹⁴C]NCI172112. However, by 24 h, approx.50% of dose is recovered in the urine with both labelled materials. Clearance of radioactivity in the faeces is slow, but, as for the renal excretion, is significantly greater for the hydantoin-¹⁴C moiety. No radioactivity is found in the expired air of a rat receiving a single dosing of [hydantoin-¹⁴C]NCI172112 and less than 1% is measured after administration of [ethyl-¹⁴C]NCI172112. Renal clearance of radioactivity is similar 4 h after administration of [¹⁴C]NCI172112 to rats with biliary cannulas, with 14.1±2.9 and 17.5±2.1% of the ethyl-¹⁴C and 34.5±2.5 and 33.1±6.3%, of the hydantoin-¹⁴C dose appearing in the urine after dosing with 3.13 and 6.25 mg/kg, respectively. A difference in the 4 h urinary excretion of the two labels also is observed in dogs given [¹⁴C]NCI172112 (1 mg/kg, i.v.). The percentages of hydantoin-¹⁴C and ethyl-¹⁴C eliminated are 29.4±2.7% and 17.2±3.5%, respectively (P<0.05).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Brown TD, et al. A phase I trial of spirohydantoin mustard (NSC 172112) in patients with advanced cancer. J Clin Oncol. 1986 Aug;4(8):1270-6.  [Content Brief]

  . Plowman J, et al. The disposition of spirohydantoin mustard (NSC 172112) in rats and dogs. Xenobiotica. 1979 Jun;9(6):379-91.  [Content Brief]